Solutions
Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
Insights
Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.
Our Solutions
News and Events
AMCP Annual Meeting 2019 Panel Discussion: Perspectives in Gene Therapy Management
Jane Barlow, MD, MPH, MBA
Real Endpoints
The potential for gene therapy to transform the treatment of a wide variety of health conditions has important implications for many stakeholders. During this panel discussion, participants will have the opportunity to hone in on pressing issues raised throughout the conference and discuss these issues with a panel of experts with varying backgrounds, including both clinical and managed care perspectives.
AMCP Annual Meeting 2019 – Financial Models to Manage Drug Spend of Gene Therapy
Jane Barlow, MD, MPH, MBA
Real Endpoints
Innovative and novel financing and reimbursement strategies may be needed to support sustainable patient access to these new treatments. During this session, managed care and provider strategies for addressing gene therapy will be explored.
Bio CEO and Investor Conference: Navigating Payers’ Expectations for Value-Based Agreements
Panelist: Roger Longman
Real Endpoints
Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy’s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers’ expectations for future models of reimbursing treatments based on outcomes versus delivery.
Jeff Berkowitz Takes Helm of Real Endpoints
by PharmaVoice
Real Endpoints, which provides development and implementation of proprietary tools, has named Jeff Berkowitz as CEO and member of the board of directors. Most recently, Mr. Berkowitz served as an executive VP at UnitedHealth Group, CEO of it Optum International business, and as a strategic leader of OptumRx, its PBM, Mr. Berkowitz is a PharmaVOICE Red Jacket - 2014.
Recent Insights
view archive >
February 13, 2019
Examining New Payment Ideas for Curative Therapies
How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."
read full insight article >
January 28, 2019
AstraZeneca strikes a ‘novel’ deal with Medicare plan to lower patient out-of-pocket costs
In a novel bid to lower medicine costs, a drug maker has agreed to adjust the discounts that a Medicare Part D plan will receive for a treatment based on how patients respond — and the deal automatically lowers out-of-pocket costs for patients, as well. “One of the major problems we have in getting drug therapy used by people who really need it is that, for those people who are on Medicare, who have to pay co-insurance or copays, there is no really good way for manufacturers to provide copay assistance, because they are not allowed to do so,” said Roger Longman.
read full insight article >National Business Director
Top 5 Pharma
Senior Director
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
Jack Bailey
President , GlaxoSmithKline U.S.